You have read all your free articles, to continue reading subscribe to read the rest of this content.
Data from the first dose group in the SpagoPix phase I trial show that SN132D is well tolerated, and provide valuable information for optimization of MRI in the next step. Now that the study continues into the next dose level the company intend to up the pace in patient recruitment…
Oncorena has announced the initiation of the Phase I-II clinical trial of orellanine in patients with advanced kidney cancer on dialysis. The drug candidate orellanine is being developed for organ-specific chemotherapy with curative potential for patients with advanced kidney cancer undergoing diAlready a subscriber Login You have read all your…
Lundbeck has announced that the phase IIa study (AMBLED) of its novel selective positive allosteric modulator of the glutamate 4 receptor, foliglurax, for the treatment of Parkinson's disease did not meet the primary study endpoint. There was no statistically significant difference in change fromAlready a subscriber Login You have read…
The European Medicines Agency has agreed on policy on publication of clinical trial data with more user-friendly amendments. This will not only allow the Agency to proactively publish clinical trial data that are submitted as part of marketing authorisation applications, but also give the possibiAlready a subscriber Login You have…
